NursingCase studyPsychopharmacology

NURS 6630 Week 4: bipolar disorder case study guide

A NURS 6630 decision-tree case study in which three prescribing decisions each have to be justified, predicted and then reconciled against what the interactive case actually returned — with the client's ancestry doing real pharmacokinetic work rather than serving as background detail.

Aug 8, 2026Updated Aug 15, 2026

Editorial process

Last reviewed · August 8, 2026

Written by

Aaron Bishop

MA, Education

assignment interpretation and research-methods coaching across disciplines

Reviewed by

Dr. Nathan Cole

PhD, Rhetoric & Composition

Argumentation and thesis development

On this page

Interpret the task
Assignment instructions
Deliverables
Proposed outline
Research plan
Reference shortlist
Final review

What is the NURS 6630 Week 4 bipolar assignment actually asking?

The shape of this assignment is a loop, not a list, and missing that is the most expensive mistake available here. At each of the three decision points the brief asks you to justify the choice, state what you hoped it would achieve, and then — this is the clause students skip — explain any difference between what you expected and what the case actually returned, and why they differed. That last question is asked three separate times, so it is roughly a quarter of the paper by volume, and it cannot be answered in advance. Note also that Decision #1 carries a fourth sub-question the other two do not: it opens with *Which decision did you select?*, because at that point the reader has no idea which branch you took. Answer the sub-questions the brief actually lists under each decision rather than applying a uniform template to all three.

Because the outcomes come from an interactive media file rather than from you, this paper has to be written after the case is run and not before. The Laureate case study is designed so that reasonable choices still produce imperfect results — partial response, an adverse effect, a client who stops taking the drug — and the *explain any difference* clause exists precisely to harvest that. A paper in which all three decisions went exactly as intended reads as though the case was never opened, and it leaves that recurring sub-question with nothing to answer. Treat an unexpected outcome as the most valuable material you have rather than as evidence you chose wrongly: the assignment is assessing clinical reasoning under feedback, and a well-argued decision that underperformed demonstrates more of that than a lucky one.

The instruction to consider factors affecting pharmacokinetic and pharmacodynamic processes is the technical core, and the brief signposts what it means by it. The case is titled *An Asian American Woman With Bipolar Disorder*, and among the required readings sits a study of CYP2D6 genotype and paroxetine pharmacokinetics in healthy Chinese subjects. Those two facts together are the assignment telling you where to look. The reduced-function CYP2D6*10 allele is markedly more common in East Asian populations than in European ones, which shifts the predicted metaboliser phenotype distribution and therefore exposure at a standard dose. If carbamazepine appears anywhere in your reasoning, HLA-B*15:02 and its ancestry-linked prevalence belong in the discussion as well. Write the mechanism, not the label. Be careful with the inference running the other way, too: ancestry is a population-level proxy and not a genotype, so the defensible claim is that dose caution or testing is warranted for this client, never that she necessarily carries the allele.

There is a trap in the resource requirement that is easy to read past. The brief asks for a minimum of three academic resources and then states that the course text may be used but *will not count toward the resource requirement*. Stahl is the course text. So a reference list of Stahl's psychopharmacology, Stahl's illustrated mood stabilizers and the Stahl chapters is a list of zero qualifying resources, and that is a mechanical failure no amount of good clinical reasoning recovers. Build the three from the peer-reviewed literature and the treatment guidelines, then add Stahl on top if it helps you. The two journal articles already sitting in the required readings both count, which means the brief has handed you two of the three before you search for anything. Check the reference list against that rule before you submit, because it is the one requirement on this brief a marker can verify in seconds and without reading a word of your argument.

Ethics is a separate deliverable, not a subsection of the third decision. The brief adds it with *also include how ethical considerations might impact your treatment plan and communication with clients*, and the learning objectives extend it to legal implications of prescribing across the lifespan. The specific content is available from the case rather than from general principles: informed consent that has to cover a genuinely uncertain risk profile, whether pharmacogenetic testing is offered before rather than after an adverse event, how teratogenic risk is discussed with a woman of childbearing age, and what changes when the client is an adolescent or an older adult. Name the consideration, tie it to a decision you actually made, and say what you would have communicated differently. The lifespan framing in the learning objectives is a hint about scope: what is defensible for this adult client would have to be re-argued for an adolescent or an older adult, and saying so briefly shows you noticed.

What the brief asks for	Where it sits	How it is usually lost
Which decision did you select?	Decision #1 only	Applying one template to all three points
Why did you select this decision?	All three	Asserting a preference with no evidence cited
What were you hoping to achieve?	All three	Restating the rationale in different words
Expected vs. actual, and why they differed	All three	Omitted — the single largest loss here
Ethical and legal considerations	Separate, after Decision #3	Folded into decision 3 as an afterthought
Three academic resources	Whole paper	Counting Stahl, which the brief excludes

Likely learning objectives

Inferred from the brief — check these against your own rubric.

01
Justify a prescribing decision from evidence rather than from preference.
02
Reconcile a predicted treatment response against an observed one, and account for the gap.
03
Apply ancestry-linked pharmacogenetic variation as a mechanism affecting drug exposure and risk.
04
Separate ethical and legal considerations in prescribing from the clinical rationale.

Assignment instructionsQuoted verbatim

Read the full question

Review every instruction before using the planning guidance that follows.

NURS 6630 Week 4 Assignment : Assessing and Treating Clients with With Bipolar Disorder NURS 6630 Week 4 Assignment : Assessing and Treating Clients with With Bipolar Disorder Bipolar disorder is a unique disorder that causes shifts in mood and energy, which results in depression and mania for clients. Proper diagnosis of this disorder is often a challenge for two reasons: 1) clients often present as depressive or manic, but may have both; and 2) many symptoms of bipolar disorder are similar to other disorders. Misdiagnosis is common, making it essential for you to have a deep understanding of the disorder’s pathophysiology. For this Assignment, as you examine the client case study in this week’s Learning Resources, consider how you might assess and treat clients presenting with bipolar disorder. Learning Objectives Students will:  Assess client factors and history to develop personalized plans of bipolar therapy for clients  Analyze factors that influence pharmacokinetic and pharmacodynamic processes in clients requiring bipolar therapy  Evaluate efficacy of treatment plans  Analyze ethical and legal implications related to prescribing bipolar therapy to clients across the lifespan Learning Resources Note: To access this week’s required library resources, please click on the link to the Course Readings List, found in the Course Materials section of your Syllabus. Required Readings Note: All Stahl resources can be accessed through this link provided. Stahl, S. M. (2013). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). New York, NY: Cambridge University Press. To access the following chapters, click on the Essential Psychopharmacology, 4th ed tab on the Stahl Online website and select the appropriate chapter. Be sure to read all sections on the left navigation bar for each chapter.  Chapter 6, “Mood Disorders”  Chapter 8, “Mood Stabilizers” Stahl, S. M., & Ball, S. (2009b). Stahl’s illustrated mood stabilizers. New York, NY: Cambridge University Press. To access the following chapters, click on the Illustrated Guides tab and then the Mood Stabilizers tab.  Chapter 4, “Lithium and Various Anticonvulsants as Mood Stabilizers for Bipolar Disorder”  Chapter 5, “Atypical Antipsychotics as Mood Stabilizers for Bipolar Disorder” Vitiello, B. (2013). How effective are the current treatments for children diagnosed with manic/mixed bipolar disorder? CNS Drugs, 27(5), 331-333. doi:10.1007/s40263-013- 0060-3 Chen, R., Wang, H., Shi, J., Shen, K., & Hu, P. (2015). Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems. European Journal of Clinical Pharmacology, 71(7), 835-841. doi:10.1007/s00228-015-1855-6 Required Media Laureate Education. (2016f). Case study: An Asian American woman with bipolar disorder [Interactive media file]. Baltimore, MD: Author Note: This case study will serve as the foundation for this week’s Assignment. Optional Resources Mostafavi, A., Solhi, M., Mohammadi, M., Hamedi, M., Keshavarzi, M., & Akhondzadeh, S. (2014). Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial. Acta Medica Iranica, 52(10), 734-739. Retrieved from http://acta.tums.ac.ir/index.php/acta NURS 6630 Week 4 Assignment Assessing and Treating Clients with With Bipolar Disorder To prepare for this Assignment:  Review this week’s Learning Resources. Consider how to assess and treat clients requiring bipolar therapy. The Assignment Examine Case Study: An Asian American Woman With Bipolar Disorder. You will be asked to make three decisions concerning the medication to prescribe to this client. Be sure to consider factors that might impact the client’s pharmacokinetic and pharmacodynamic processes. At each decision point stop to complete the following:  Decision #1 o Which decision did you select? o Why did you select this decision? Support your response with evidence and references to the Learning Resources. o What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources. o Explain any difference between what you expected to achieve with Decision #1 and the results of the decision. Why were they different?  Decision #2 o Why did you select this decision? Support your response with evidence and references to the Learning Resources. o What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources. o Explain any difference between what you expected to achieve with Decision #2 and the results of the decision. Why were they different?  Decision #3 o Why did you select this decision? Support your response with evidence and references to the Learning Resources. o What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources. o Explain any difference between what you expected to achieve with Decision #3 and the results of the decision. Why were they different? Also include how ethical considerations might impact your treatment plan and communication with clients. Note: Support your rationale with a minimum of three academic resources. While you may use the course text to support your rationale, it will not count toward the resource requirement. Submission and Grading Information To submit your completed Assignment for review and grading, do the following:  Save your Assignment using the naming convention “WK4Assgn+last name+first initial.(extension)” as the name.  Click on the Assignment Rubric to review the Grading Criteria for the Assignment.  Click on the Week 4 Assignment link. Next, from the Attach File area, click on the Browse My Computer button. Find the document you saved as “WK4Assgn+last name+first initial.(extension)” and click on Open.  If applicable: From the Plagiarism Tools area, click in the checkbox for I agree to submit my paper(s) to the Global Reference Database. Grading Criteria To access your rubric: Week 4 Assignment Rubric Check Your Assignment Draft for Authenticity To check your Assignment draft for authenticity: Submit your Week 4 Assignment draft and review the originality report. Submit Your Assignment by Day 7 To submit your Assignment: Week 4 Assignment

What each decision point has to contain

01
Three prescribing decisions, each addressed at its own decision point.
02
For Decision #1, an explicit statement of which option was selected.
03
For each decision: rationale, intended outcome, and expected-versus-actual reconciliation.
04
A discussion of ethical considerations affecting the treatment plan and client communication.
05
A minimum of three academic resources, excluding the course text.
06
APA formatting, and the file named WK4Assgn+last name+first initial.

Structuring three decisions and the ethics requirement

Introduction and client presentation

Establish the client, the presenting features, and the diagnostic uncertainty the brief opens with.

Decision #1 — selection, rationale, intent

Name the option chosen and justify it against the evidence, then state the intended outcome.

Decision #1 — expected versus actual

Compare the predicted response to what the case returned and account for the difference.

Decisions #2 and #3, each on the same three questions

Carry the rationale, intent and reconciliation forward as the case narrows.

Pharmacokinetic and pharmacodynamic factors for this client

Set out the ancestry-linked metabolic and immunogenetic factors that bear on the agents considered.

Ethical and legal considerations

Address consent, risk disclosure and lifespan-specific legal exposure as they affect this plan.

Which sources count toward the three-resource minimum?

Recommended databases

PubMed
NCBI Bookshelf — Medical Genetics Summaries
CINAHL
The Walden Library Course Readings List for NURS 6630

Search sequence

1.
Start with the two journal articles already in the required readings. Both are peer-reviewed and both count toward the three-resource minimum, so the brief has supplied two-thirds of the requirement before you search at all.
2.
Retrieve a current treatment guideline for bipolar disorder and use its ranked first-line options as the evidence base for the rationale at each decision point, rather than arguing from a single trial.
3.
Search the pharmacogenetic literature for the specific agent you selected paired with the relevant gene — CYP2D6 for agents cleared by that enzyme, HLA-B for carbamazepine — so the ancestry discussion cites frequency data rather than asserting a difference.
4.
Run the case before finalising the search. Which sources you need depends on which branch the case took, and searching first tends to produce a reference list arguing for a decision you did not make.

Guidelines and pharmacogenetic sources for this case

These are authoritative starting points, not a ready-made bibliography. A qualified reviewer must confirm that each source fits the assignment and supports the claim beside which it is cited.

Nothing here is cleared for citation until you have read it.

01
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
Bipolar Disorders (via PubMed) — Yatham, Kennedy, Parikh et al. · 2018
The ranked first-line options for acute mania and for bipolar I depression, which is what turns a decision rationale from a preference into an evidence-based choice. Use it to justify why the agent you selected sits where it does in the hierarchy. It also carries recommendations for specific populations, which feeds the lifespan element of the ethics section.
02
Lithium — StatPearls
StatPearls Publishing, via NCBI Bookshelf · 2024
Pre-treatment kidney and thyroid testing, trough sampling at 8-12 hours, and the therapeutic ranges — the monitoring detail that makes a lithium rationale concrete. Useful for the expected-versus-actual sections, because a narrow therapeutic index is a mechanism by which a reasonable decision produces an unexpected result.
03
Carbamazepine Therapy and HLA Genotype — Medical Genetics Summaries
National Center for Biotechnology Information, NCBI Bookshelf · 2018
The source for the immunogenetic half of the ancestry argument if carbamazepine features in any decision. It gives FDA-referenced HLA-B*15:02 prevalence by population and the recommendation to test before initiating. This is the difference between writing that ethnicity matters and showing why, with a figure attached.
04
CYP2D6 Overview: Allele and Phenotype Frequencies — Medical Genetics Summaries
National Center for Biotechnology Information, NCBI Bookshelf · 2025
Population-level allele and predicted-phenotype frequencies, including the elevated frequency of the reduced-function CYP2D6*10 allele in East Asian populations. This is what lets the pharmacokinetic discussion state a mechanism for altered exposure rather than gesturing at genetic variation in general.
05
Informed Consent — StatPearls
StatPearls Publishing, via NCBI Bookshelf · 2024
The elements consent has to cover and the capacity questions that arise when a client is acutely manic or is a minor. Anchors the ethics section on what must actually be disclosed and documented, instead of the generic appeal to autonomy and beneficence that this requirement usually attracts.

Before the Week 4 assignment is uploaded

Common mistakes

Omitting the expected-versus-actual comparison, which the brief asks for three separate times.
Writing the paper before running the interactive case, so every outcome matches the prediction.
Treating an unexpected result as a wrong answer to be hidden rather than as the material being assessed.
Applying an identical four-part template to all three decisions when only Decision #1 asks which option was chosen.
Reducing pharmacokinetics and pharmacodynamics to a definition paragraph with no link to this client.
Mentioning the client's ethnicity as cultural background without naming a metabolic or immunogenetic mechanism.
Counting Stahl toward the three required resources when the brief explicitly excludes the course text.
Folding ethics into the third decision instead of addressing it as its own requirement.

Submission checklist

All three decision points are present and separately headed.
Decision #1 states which option was selected.
Each decision answers the expected-versus-actual question with a reason for the gap.
At least one named pharmacokinetic or pharmacodynamic factor is tied to this specific client.
Ethical and legal considerations appear as their own section.
Three or more academic resources are cited, none of them the course text.
Every rationale carries a citation rather than a bare assertion.
The file is named to the WK4Assgn convention before upload.

Use this guide to plan and review your own work. Follow your institution's rules and read our academic-integrity policy.